Streetbeat News

NRSN

NeuroSense Therapeutics Ltd.

https://www.neurosense-tx.com

Industry

Biotechnology

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Open

1.25

Mkt cap

23M

Volume

121K

High

1.26

P/E Ratio

-1.82

52-wk high

2.33

Low

1.14

Div yield

N/A

52-wk low

0.47

NeuroSense Therapeutics plans to submit its dossier in Q2 2025, with a regulatory decision on commercialization expected by Q1 2026.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 12:00 pm

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) is preparing for an FDA Type C meeting to discuss its Phase 3 trial design for PrimeC, a potential ALS treatment. The meeting is a crucial step towards FDA approval and a future NDA submission. NeuroSense is also planning a regulatory submission to Health Canada, with a potential market opportunity of $100-150 million annually. The company is in talks with major pharmaceutical firms for a strategic partnership.

Portfolio Pulse from Vandana Singh

October 28, 2024 | 12:00 pm

NeuroSense Therapeutics is focusing on finalizing the design for its Phase 3 study and ensuring NDA readiness, aiming for a clear regulatory path for submission based on trial success.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 12:00 pm

NeuroSense Therapeutics has secured a crucial meeting with the FDA to advance its Phase III trial and NDA submission for its ALS treatment. This development is a significant step forward for the company in its efforts to bring its treatment to market.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 12:00 pm

NeuroSense Therapeutics Ltd. plans to submit a dossier for early commercialization of its ALS treatment, PrimeC, in Canada by Q2 2025, with a regulatory decision expected by Q1 2026. The company estimates a potential market opportunity of $100M-$150M in annual revenue.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:24 pm

NeuroSense Therapeutics shares rise as the company seeks early commercialization approval for PrimeC in ALS under Health Canada's policy.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 1:07 pm

NeuroSense Therapeutics is seeking early commercialization approval for its drug PrimeC, aimed at treating ALS, under Health Canada's Notice of Compliance with Conditions policy.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 1:04 pm

NeuroSense Therapeutics has announced the acceptance of two abstracts related to their ALS treatment, PrimeC, for presentation at the 2024 NEALS Annual Meeting. This event will take place from October 21-24 in Clearwater, Florida.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 1:04 pm

NeuroSense Therapeutics has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the exchange. This development is crucial for maintaining investor confidence and access to capital markets.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:07 pm

NeuroSense Therapeutics has been granted a U.S. patent for its novel PrimeC formulation, extending its intellectual property protection through 2042. This strengthens the company's IP position by adding four additional years to its coverage.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.